Healthcare Sector Analytics

Market size, company revenue, drug approvals, clinical trials, regulation, hospitals, doctors, drug spending, labs and devices

Brand drugFirst approved 2005

Asmanex(Mometasone Furoate)Organon & Co. logoOGN

Medicare prescription drug cost, prescriptions and prescribers, 2024 · made by Organon & Co.

$6.5M

Medicare cost, 2024

Medicare drug plans spent $6.5 million on Asmanex (mometasone furoate) in 2024, for 35,687 prescriptions and refills filled by 11,728 patients. Spending fell 55% from 2023 to 2024. Pennsylvania accounts for the most spending ($700,479, 11% of the total). It is made by Organon & Co. (OGN).

Medicare cost, 2024

$6.5M

-55.4% from 2023

Prescriptions

36K

$182.39 per claim

Patients

12K

10,954 prescribers

Total spending, 2024

$6.5M

$555.09 per patient

Questions and answers

How much does Medicare spend on Asmanex?

Medicare prescription drug plans paid $6.5M for Asmanex in 2024, for 35,687 prescriptions and refills to 11,728 patients (down 55.4% from 2023). The average cost per claim was $182.39.

Which state spends the most on Asmanex?

Pennsylvania had the highest Medicare cost for Asmanex in 2024: $700K for 4,035 claims, followed by New York ($456K).

Who prescribes Asmanex the most?

Christopher Faber, pulmonary disease in Pittsburgh, PA, had the highest Medicare cost for Asmanex in 2024: 73 claims costing $9,415.

Who makes Asmanex?

Asmanex is made by Organon & Co. (OGN), listed in the Medicare spending data as Organon LLC.

Spending over the years

Medicare spending by year

All plans and makers

Prescriber data: cost by year

Medicare spending on Asmanex was $6.5M in 2024, after a high of $15.7M in 2022.

By state

Where the prescribers practice, 2024

Medicare cost by state

States with the highest cost

Top prescribers of Asmanex, 2024

By Medicare drug cost

PrescriberTypeClaimsPatientsCost
Christopher Faber Pittsburgh, PAPulmonary Disease7316$9,415
Schuman Tam San Francisco, CAAllergy/ Immunology34Under 11$8,142
Kaiser G Lim Rochester, MNPulmonary Disease21Under 11$7,809
Jason B Karp Lake Success, NYPulmonary Disease29Under 11$7,595
John Russomanno Hartford, CTPulmonary Disease39Under 11$7,344
Eric J Schenkel Bethlehem, PAAllergy/ Immunology21Under 11$7,177
Richard F Kucera Greensburg, PAPulmonary Disease3911$6,856
Kenneth A Johns Coon Rapids, MNAllergy/ Immunology46Under 11$6,758
Jose J Gomez Idabel, OKFamily Practice5411$6,725
Michael Schatz San Diego, CAAllergy/ Immunology28Under 11$6,514
Natalie A Brixey Tishomingo, OKFamily Practice50Under 11$6,277
Yasir Hatahet Fond Du Lac, WIPulmonary Disease43Under 11$6,258
Richard N Krinsky Winsted, CTPulmonary Disease40Under 11$6,023
Keith Harmon St Louis Park, MNPulmonary Disease31Under 11$5,980
Tyree L Seals Fort Smith, ARInternal Medicine5613$5,907
Rajesh C Patel Riverhead, NYInternal Medicine2011$5,489
Mark Lowenthal Orland Park, ILAllergy/ Immunology19Under 11$5,338
Lianne L Lin Beaverton, ORPulmonary Disease23Under 11$5,250
Donna M Romito Norwich, CTPulmonary Disease19Under 11$5,207
Karen M Schaller Bethlehem, PANurse Practitioner19Under 11$5,060
Ramesh B Avula Lansing, MIAllergy/ Immunology14Under 11$5,035
Bryan Farthing Anchorage, AKPhysician Assistant19Under 11$4,970
Brian P Burlew Bethlehem, PAInternal Medicine2511$4,894
Gary W Price Lakeland, FLAllergy/ Immunology11Under 11$4,871
John J Solic State College, PAPulmonary Disease32Under 11$4,869

Prescriber data by year

YearPrescribersClaimsPatientsCost
202211,47142,54112,433$16.0M
202310,43838,00611,074$14.6M
202410,95435,68711,728$6.5M

Makers, 2024

Spending by manufacturer as listed in the spending data

ManufacturerClaimsSpending
Organon LLCOGN logoOGN35,699$6.5M

Medicaid spending by quarter

Amount reimbursed by state Medicaid programs, all states

Amount reimbursed

Codes

National drug codes (packages)
5
RxNorm concept IDs
746803, 746804, 746810, 746811, 746812
Application numbers
NDA021067

More drugs: Medicare drug spending and the Prescriptions view.

Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.

LinkedInLinkedInXXYouTubeYouTube